UCB's Global Corporate Website

This section is intended for media and financial analysts

Acquisition of own shares

Brussels (Belgium), 14 June 2024 – 20:00 (CEST) – Regulated information 

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV (“UCB” or the “Company) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2024. 

Under this program, UCB has requested a financial intermediary to repurchase up to 1,300,000 UCB shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 30 June 2024, effective as from 02 April 2024, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2024, UCB repurchased 142,933 UCB shares on Euronext Brussels in the period from 07 June 2024 up to and including 13 June 2024, as follows: 

This press release is available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14

Corporate Communications
Laurent Schots 
T+32 2 559 92 64

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Asset Download

Stay up-to-date on the latest news and information from UCB